Pence-Aligned Group Blasts Trump’s Drug Pricing Policy in Ad Campaign

A conservative group founded by former Vice President Mike Pence is launching a new campaign targeting a central element of President Donald Trump’s drug pricing strategy, escalating an ideological clash inside the…

Andrew PowellNov 17, 20253 min read

Sponsored

would jeopardize U.S. leadership in pharmaceutical development.

“If politicians in Washington start to place price controls on our most innovative products, like prescription drugs, we’ll be handing over American jobs and life-saving research to China on a silver platter,” the narrator says.

It concludes with a call to action: “Tell Congress to say ‘no’ to China by saying ‘no’ to MFN price controls.”

While the campaign is aimed at the GOP-controlled Congress, it represents a direct critique of Trump, who has rolled out multiple MFN-related proposals in recent months.

Earlier this month, Trump announced agreements with Eli Lilly & Co. and Novo Nordisk to reduce prices on high-demand medications, including weight-loss and diabetes drugs such as Ozempic and Wegovy. The White House said MFN pricing will apply to “all new medicines” brought to market.

Trump said the agreements would cut costs by hundreds of dollars and praised the initiative as “a triumph for American patients that will save lives and improve the health of millions and millions of Americans.” The discounted prices will be available through a website called TrumpRx.

However, AAF has long warned that MFN policies could harm pharmaceutical innovation. A memo released by the group in September argued the move could “mean significant reductions in American research and development.”

“More regulations and red tape will result in fewer cures and life-saving drugs coming to market, ultimately costing American lives,” Chapman said. “Advancing American Freedom strongly supports the power of free markets. To deliver lower prices for Americans, we need fewer government regulations, not more.”

The dispute marks another break between Pence’s organization and President Trump. AAF has already criticized Trump’s use of tariffs and his recent call to end the Senate filibuster.

The White House fired back sharply at AAF’s latest claims. Spokesman Kush Desai dismissed the criticism as baseless.

“Anyone calling President Trump’s historic Drug pricing deals ‘price controls’ is either too stupid or dishonest to be taken seriously,” Desai told Fox News Digital. “President Trump’s deals are equalizing this burden by making other wealthy countries shoulder their fair share for the pharmaceutical innovation that’s saving lives — thereby restoring the free market principles that Mike Pence supposedly supports.”

As the internal GOP battle over Drug pricing intensifies, both sides appear poised to continue pressing their message — with Trump defending his policy as pro-patient, and Pence’s group arguing it threatens the innovation that made U.S. drug companies global leaders.